Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)
Active, not recruitingOBSERVATIONAL
Enrollment
50,000
Participants
Timeline
Start Date
November 1, 2024
Primary Completion Date
January 30, 2025
Study Completion Date
June 15, 2025
Conditions
Type 2 Diabetes
Interventions
DRUG
Tirzepatide
Tirzepatide
DRUG
Dulaglutide
Dulaglutide
Trial Locations (1)
02120
Brigham and Women's Hospital, Boston
All Listed Sponsors
lead
Brigham and Women's Hospital
OTHER
NCT06779929 - Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT) | Biotech Hunter | Biotech Hunter